Advertisement
News
Subscribe to MDT Magazine News

Pacira Pharmaceuticals, Inc. Announces Pricing of Its Initial Public Offering

February 3, 2011 4:36 am | by Bio-Medicine.Org | Comments

PARSIPPANY, N.J., Feb. 3, 2011 /- Pacira Pharmaceuticals, Inc. (Nasdaq: PCRX ), an emerging specialty pharmaceutical company, today announced the pricing of its initial public offering of 6,000,000 shares of its common stock at $7.00 per share, before underwriting discounts and...

TOPICS:

Valeant Launches Senior Notes Offering

February 3, 2011 4:36 am | by Bio-Medicine.Org | Comments

MISSISSAUGA, Ontario, Feb. 3, 2011 /- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ) (TSX: VRX) (the "Company") announced today that Valeant Pharmaceuticals International ("Valeant"), its wholly owned indirect subsidiary, launched its offer of approximately $650 million...

TOPICS:

BioNeutral Group Announces the Formation of Kentucky-Based BioNeutral Services, Inc. and the Appointment of Frank Battafarano as Chairman and CEO of BioNeutral Services, Inc.

February 3, 2011 4:36 am | by Bio-Medicine.Org | Comments

NEWARK, N.J., Feb. 3, 2011 /- BioNeutral Group, Inc. (OTC Bulletin Board: BONU ), a specialty life science technology-based company, today announced the formation of BioNeutral Services, Inc., a wholly owned subsidiary of BioNeutral Group, Inc., and the appointment of Frank Battafarano as...

TOPICS:
Advertisement

Amarin names Huff to lead cholesterol drug commercialization

February 3, 2011 4:35 am | by Mass High Tech: The Journal of New England Technology | Comments

Amarin Corp. plc, an Irish biotech with U.S. research and development headquarters in Mystic, Conn., has named Paul Huff, an industry veteran with cholesterol drug commercialization under his belt, as chief commercial officer.

TOPICS:

AVEO Pharmaceuticals starts exploratory biomarker trial enrollment

February 3, 2011 4:35 am | by Mass High Tech: The Journal of New England Technology | Comments

Cambridge-based AVEO Pharmaceuticals Inc. said it has started enrolling patients in a Phase 2 exploratory biological marker study of tivozanib, its lead treatment for renal cell carcinoma (RCC).

TOPICS:

NMT Medical bumped from Nasdaq, moves to OTCQB trading

February 3, 2011 4:34 am | by Mass High Tech: The Journal of New England Technology | Comments

NMT Medical Inc., a Boston provider of cardiac implants, is moving its securities trading to the OTCQB, following the company's 2010 notice that it failed to meet the minimum requirements to trade on the Nasdaq Capital Market.

TOPICS:

CardioVascular BioTherapeutics Submits FDA Application for 'Fast Track' Status for CVBT-141B, CVBT's Biological Treatment for Diabetes Patients

February 3, 2011 4:34 am | by Bio-Medicine.Org | Comments

LAS VEGAS, Feb. 3, 2011 /- CardioVascular BioTherapeutics, Inc. (Pink Sheets: CVBT ) today announced it has submitted an application to the U.S. FDA to obtain "fast track" designation for CVBT-141B, its biological therapy to treat ischemic diabetic wounds based on the active ingredient...

TOPICS:

Generex Oncology Receives New Patent for AE37 Immunotherapeutic Cancer Vaccine

February 3, 2011 4:33 am | Comments

WORCESTER, Mass., Feb. 3, 2011 /- Generex Biotechnology Corporation ( www.generex.com ) (OTC Bulletin Board: GNBT ), together with its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, Inc. ( www.antigenexpress.com ), announced today that Antigen Express has received a...

Advertisement

Unilife Appoints Dr. Ramin Mojdeh as Chief Operating Officer

February 3, 2011 4:32 am | by Bio-Medicine.Org | Comments

YORK, Pa., Feb. 3, 2011 /- Unilife Corporation ("Unilife" or the "Company") (Nasdaq: UNIS ; ASX: UNS) today announced that it has appointed Dr. Ramin Mojdeh, formerly Vice President and General Manager of Becton Dickinson (BD) Pharmaceutical Systems, North America, and Worldwide Vice...

TOPICS:

Invacare 4Q profit falls on debt costs

February 3, 2011 3:45 am | by The Associated Press | Comments

Invacare Corp., which makes wheelchairs, crutches and motorized scooters, said Thursday its fourth-quarter profit plunged on debt costs.But the company's forecast for adjusted earnings for 2011 topped Wall Street estimates.The company said its net income dropped to $7.2 million, or 22 cents per...

CareFusion to Sell International Surgical Products Distribution Business to Medline for $130 Million(2)

February 3, 2011 2:38 am | by Bio-Medicine.Org | Comments

SAN DIEGO and MUNDELEIN, Ill., Feb. 3, 2011 /- CareFusion Corporation (NYSE: CFN ) a global, medical technology company, and Medline Industries, Inc. , the nation's largest privately held manufacturer and distributor of healthcare products, today announced an agreement to sell the...

TOPICS:

Corium International Adds Dr. Bhaskar Chaudhuri and David Greenwood to Board of Directors

February 3, 2011 2:37 am | by Bio-Medicine.Org | Comments

MENLO PARK, Calif., Feb. 3, 2011 /- Corium International, Inc., a privately-held advanced transdermal drug delivery company, today announced the appointment of Dr. Bhaskar Chaudhuri and David L. Greenwood to the Board of Directors.  Dr. Chaudhuri most recently served as President of...

TOPICS:

CareFusion to Sell International Surgical Products Distribution Business to Medline for $130 Million

February 3, 2011 2:36 am | Comments

SAN DIEGO and MUNDELEIN, Ill., Feb. 3, 2011 /- CareFusion Corporation (NYSE: CFN ) a global, medical technology company, and Medline Industries, Inc. , the nation's largest privately held manufacturer and distributor of healthcare products, today announced an agreement to sell the...

Insurer Cigna's 4Q profit jumps 40 percent

February 3, 2011 1:45 am | by The Associated Press | Comments

Managed care company Cigna says its fourth-quarter profit climbed 40 percent, boosted in part by interest rates and a decline in health care use that also helped other insurers in the final months of 2010.The Philadelphia insurer says it earned $461 million, or $1.69 per share, in the three...

Inspiration Biopharmaceuticals Demonstrates Non-Inferiority of IB1001, Its Recombinant Factor IX for Hemophilia B

February 2, 2011 10:36 pm | by Bio-Medicine.Org | Comments

GENEVA, Feb. 3, 2011 /- Inspiration Biopharmaceuticals, Inc. (Inspiration) today presented pharmacokinetic (PK) data on its lead product, IB1001, a recombinant factor IX (FIX) for the treatment and prevention of bleeding in individuals with hemophilia B.  Results of the Phase 1...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading